BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37304239)

  • 1. A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker.
    Huang Y; Zhou X; Li X; Huang D; Fang Z; Ding R
    Oncol Res; 2023; 31(2):193-205. PubMed ID: 37304239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of
    Guo X; Zhou S; Yang Z; Li ZA; Hu W; Dai L; Liang W; Wang X
    Front Oncol; 2022; 12():896433. PubMed ID: 35646697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive prognostic and immune analysis of sterol O-acyltransferase 1 in patients with hepatocellular carcinoma.
    Gan CJ; Zheng Y; Yang B; Cao LM
    World J Hepatol; 2024 Mar; 16(3):439-451. PubMed ID: 38577529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic pan-cancer analysis identifies cuproptosis-related gene DLAT as an immunological and prognostic biomarker.
    Xu L; Wu P; Rong A; Li K; Xiao X; Zhang Y; Wu H
    Aging (Albany NY); 2023 May; 15(10):4269-4287. PubMed ID: 37199628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
    Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
    Front Immunol; 2022; 13():844736. PubMed ID: 35592314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers.
    Qi J; Wu G; He M; Xu Y; Yang Z; Ding L; Wang Y; Zhang Z
    Aging (Albany NY); 2024 Jan; 16(2):1879-1896. PubMed ID: 38261737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
    Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
    Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
    Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
    Front Immunol; 2022; 13():837512. PubMed ID: 35401558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
    Liu C; Zhang W; Zhou X; Liu L
    Front Immunol; 2022; 13():983490. PubMed ID: 36618420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The circadian rhythm key gene
    Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
    Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer.
    Yu Y; Sun Y; Li Z; Li J; Tian D
    BMC Bioinformatics; 2023 Feb; 24(1):44. PubMed ID: 36765282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Multiomic Analysis Identified TUBA1C as a Potential Prognostic Biological Marker of Immune-Related Therapy in Pan-Cancer.
    Zou Y; Wang G; Fan M
    Comput Math Methods Med; 2022; 2022():9493115. PubMed ID: 36466547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
    Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
    Front Genet; 2022; 13():938510. PubMed ID: 36171879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.